Sipuleucel-T

A Dive Into the Data Showing African American Men Do Better Than Caucasian Men with Provenge And All Men Live Longer If They Receive Provenge When Their PSA Scores Are Low

 African American men face many different health disparities with most of the disparities being weighed against them.  There is one notable exception, African American (AA) men have a huge, significant overall survival benefit when given Sipuleucel-T (Provenge) equal to 9.5 months over their Caucasian counterparts!

Provenge and Clinical Outcomes by Baseline PSA Level

Provenge (Sipuleucel-T) is the first FDA approved cancer vaccine and it is still the only immune therapy approved for Prostate Cancer. In a post-hoc analysis it was demonstrated that those men who have lower PSA scores had a superior overall survival. The analysis also showed that men who had Provenge treatment have a lower risk of cardiovascular events.